Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastomaBianca M. Marin, Jann N. Sarkaria, Ju‐Hee Oh et al.|Neuro-Oncology|2021Cited by 81
Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling NetworksIshwar N. Kohale, Forest M. White, Danielle M. Burgenske et al.|Cancer Research|2021Cited by 37
Multimodal platform for assessing drug distribution and response in clinical trialsBegoña Giménez, Nathalie Y.R. Agar, Ishwar N. Kohale et al.|Neuro-Oncology|2021Cited by 14
WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse modelsJason E. Conage‐Pough, Forest M. White, Sylwia A. Stopka et al.|Neuro-Oncology Advances|2023Cited by 5
Abstract C051: MDM2 inhibitor KRT-232 extends survival in glioblastoma patient-derived xenograft modelsAnn C. Mladek, Jann N. Sarkaria, Shiv K. Gupta et al.|Molecular Cancer Therapeutics|2019Cited by 3